{"product_id":"krt13-antibody-sc-f2188","title":"Cytokeratin 13 Antibody","description":"\u003ch2\u003eAbout the Target\u003c\/h2\u003e\u003cp\u003eCytokeratin 13 (CK13) is a 54 kDa type I acidic cytokeratin encoded by the KRT13 gene on chromosome 17q21. It primarily forms heterodimers with type II cytokeratin CK4 and is found in the suprabasal layers of non-cornified stratified squamous epithelium, such as in the oral cavity, esophagus, and urothelium. Depending on the literature source, KRT13 may also be discussed as Cytokeratin 13 and Keratin.\u003c\/p\u003e\u003cp\u003eReported cellular context includes intermediate filament and keratin, which can matter when signal is compared across treatments or changing cell states. Following KRT13 across matched perturbations can help separate abundance effects from shifts in localization, complex assembly, or pathway state.\u003c\/p\u003e\u003ch2\u003eResearch Context\u003c\/h2\u003e\u003cp\u003eKRT13 is commonly interpreted in the context of cancer and cell signaling research, and readouts are often stronger when a study separates expression changes from compartment-level redistribution. When reported signal spans intermediate filament and keratin, a defined reference condition can make comparisons more interpretable across perturbations, passages, or replicate sets.\u003c\/p\u003e\u003cp\u003eConsider these angles when interpreting target-level changes:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eapparent redistribution between intermediate filament and keratin across matched conditions\u003c\/li\u003e\n\u003cli\u003echanges associated with proliferative state, oncogenic signaling, or treatment response\u003c\/li\u003e\n\u003cli\u003esignal-dependent shifts after ligand, inhibitor, or growth-factor perturbation\u003c\/li\u003e\n\u003cli\u003eco-patterning with orthogonal markers and control conditions that clarify pathway state\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eVariant Considerations\u003c\/h2\u003e\u003cp\u003eIf your project spans exploratory questions, the regular version offers a balanced option for establishing baseline signal behavior for KRT13. This can help when protocols evolve over time and the goal is to compare experiments using a stable reference workflow.\u003c\/p\u003e\u003cp\u003eStandardize sampling time, control choice, and downstream analysis thresholds so apparent differences in KRT13 reflect biology rather than handling. When interpreting KRT13, it is often useful to decide early whether the main question is overall abundance, compartmental enrichment, or context-dependent redistribution.\u003c\/p\u003e\u003cp\u003eFor multi-run studies, a shared reference condition can keep KRT13 trends easier to compare across datasets. That kind of consistency is especially helpful when follow-up work expands to new perturbations, model systems, or longitudinal collections.\u003c\/p\u003e","brand":"Selleck Chemicals","offers":[{"title":"20 µl","offer_id":57577886482777,"sku":"F2188-20UL","price":199.0,"currency_code":"EUR","in_stock":true},{"title":"100 µl","offer_id":57577886515545,"sku":"F2188-100UL","price":489.0,"currency_code":"EUR","in_stock":true},{"title":"2 × 100 µl","offer_id":57577886548313,"sku":"F2188-2X100UL","price":729.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0923\/1011\/0553\/files\/F2188-IF.png?v=1773600261","url":"https:\/\/absource-diagnostics.myshopify.com\/products\/krt13-antibody-sc-f2188","provider":"Absource Diagnostics","version":"1.0","type":"link"}